Literature DB >> 12189223

Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998.

Mohamed A Eltom1, Ahmedin Jemal, Sam M Mbulaiteye, Susan S Devesa, Robert J Biggar.   

Abstract

BACKGROUND: The incidence of Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL) in the general population has markedly increased since the onset of the AIDS epidemic in 1981. However, during the 1990s, the dynamics of the AIDS epidemic changed, as human immunodeficiency virus (HIV) infection rates slowed and effective antiretroviral therapies were introduced. We examined the impact of these changes on the general population incidence of KS and NHL.
METHODS: Age-standardized incidences for KS and NHL from 1973 through 1998 were obtained from nine population-based cancer registries that participate in the Surveillance, Epidemiology and End Results (SEER) program.
RESULTS: During the mid-1990s, KS incidence declined sharply in all nine registries. Decreases in KS incidence were most evident in San Francisco, where KS rates among white men had risen from 0.5 per 100 000 people per year in 1973 to between 31.1 and 33.3 from 1987 through 1991 and then declined to 2.8 in 1998. With background NHL incidence in the general population being much higher than that for KS, changes in incidence related to the AIDS epidemic were most evident in subgroups at high risk of AIDS. In San Francisco, NHL rates among white men rose from 10.7 in 1973 to a peak of 31.4 in 1995 and then declined to 21.6 in 1998. NHL types that were most highly AIDS-associated declined most steeply, whereas the incidence of NHL types not associated with AIDS was either stable or increasing.
CONCLUSION: Changes in KS and NHL incidence since the mid 1990s may reflect declines in the number of individuals with AIDS and improved immune function in such individuals following the introduction of effective antiretroviral therapies in the 1990s. Notably, non-AIDS-associated NHL incidence has continued to increase steadily through 1998.

Entities:  

Mesh:

Year:  2002        PMID: 12189223     DOI: 10.1093/jnci/94.16.1204

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  86 in total

Review 1.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.

Authors:  Ashok Cattamanchi; Misty Saracino; Stacy Selke; Meei-Li Huang; Amalia Magaret; Connie Celum; Lawrence Corey; Anna Wald; Corey Casper
Journal:  J Med Virol       Date:  2011-10       Impact factor: 2.327

3.  Kaposi's sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania.

Authors:  Phillipo L Chalya; Fidelis Mbunda; Peter F Rambau; Hyasinta Jaka; Nestory Masalu; Mariam Mirambo; Martha F Mushi; Samuel E Kalluvya
Journal:  BMC Res Notes       Date:  2015-09-15

4.  Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.

Authors:  Nadia Howlader; Lindsay M Morton; Eric J Feuer; Caroline Besson; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-10-15       Impact factor: 4.254

5.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

6.  Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base.

Authors:  Anna E Coghill; Xuesong Han; Gita Suneja; Chun Chieh Lin; Ahmedin Jemal; Meredith S Shiels
Journal:  Cancer       Date:  2019-05-03       Impact factor: 6.860

Review 7.  Diffuse large B-cell lymphoma.

Authors:  Jonathan W Friedberg; Richard I Fisher
Journal:  Hematol Oncol Clin North Am       Date:  2008-10       Impact factor: 3.722

Review 8.  Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  A J Swerdlow
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

9.  Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.

Authors:  Huong Q Nguyen; Amalia S Magaret; Mari M Kitahata; Stephen E Van Rompaey; Anna Wald; Corey Casper
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

Review 10.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.